Heat Biologics Inc. has appointed Timothy Creech as its new chief financial officer.
"With over 30 years of experience in pharmaceutical and biotechnology management, Tim is well-versed in the financial and reporting challenges facing high-growth biotechnology companies. He also brings expertise in strategic partnerships and the development and commercialization of pharmaceutical products," said Jeff Wolf, Heat's chief executive officer. "Tim will be a valuable addition to our leadership team and we look forward to his contributions as we focus on advancing our clinical programs."
Most recently, Mr. Creech served as acting chief financial officer of Salix Pharmaceutical, a publicly-held specialty pharmaceutical company acquired by Valeant for $11 billion in April 2015. Prior to this appointment for Salix, Mr. Creech held several financial leadership positions at the company over the last seven years including senior vice president, finance and administrative services. Before joining Salix in 2007, Mr. Creech served as vice president of finance and chief accounting officer at Voyager Pharmaceutical Corporation, a privately held biotechnology company.
